

# The effect of L-carnitine on gentamicin-induced nephrotoxicity and associated anaemia in adult male albino rats

Nefissa Hussein Meky<sup>1</sup>, Mohamed Islam Heibashy<sup>2</sup>, Ola Mahmoud Mahmoud<sup>3</sup>,  
Heba Abo Baker Youssef Ahmed<sup>4</sup>

<sup>1</sup>Zoology Department, Faculty of Science, Ain Shams University.

<sup>2</sup>Biological Applications Department Nuclear Research Centre, Atomic Energy Authority.

<sup>3</sup>Departments of Hematology, Theodor Bilharz Research Institute, Cairo, Egypt.

<sup>4</sup>Zoology Department, Women's College, Ain Shams University.

## Abstract

This study was conducted to evaluate the effect of L-carnitine on gentamicin-induced nephrotoxicity and anaemia in adult male albino rats. A control group (saline, group I, n = 21) was compared with rats administrated 80 mg/kg gentamicin, once daily for 10 days (groups II, n = 49). After 10 days 7 rats from each group were sacrificed for investigation. The remaining of normal control rats was served as normal control group (Group 1) (14 rats), while 42 nephrotoxic rats subdivide in to: Subgroup 2 (control 2): Nephrotoxic rats (14 rats). Subgroup 3: Nephrotoxic rats were injected intraperitoneal with L-carnitine (300 mg/kg/day) for 15 and 30 days (14 rats). Subgroup 4: Nephrotoxic rats were injected intraperitoneal with L-carnitine (600 mg/kg/day) for 15 and 30 days (14 rats). At the end of each experiment period, 7 rats from each groups were sacrificed. The effect of L-carnitine (group III and IV) was compared. The activities of biochemical parameters [urea, creatinine,  $\beta_2$ -microglobulin, potassium (K), total oxidant status (TOS)] and [iron (Fe), total iron binding capacity (TIBC) and ferritin] increased in nephrotoxic rats, while total protein, sodium (Na) and total antioxidant status (TAS) decreased and in haematological parameters osmotic fragility increased but haemoglobin and red blood cells (RBCs) decreased in nephrotoxic rats. Administration of L-carnitine improved alterations of biochemical and haematological parameters. In conclusion, this study demonstrated that treatment with L-carnitine attenuated the biochemical and haematological alterations induced by gentamicin and identifies new areas of research for development of better therapeutic agents for kidney and better dose.

**Keywords:** *L-carnitine, Gentamicin, Nephrotoxicity*

## 1. Introduction

Acute renal failures, is a sudden decline in kidney function causing disturbances in fluid, electrolyte, and acid-base balance because of a loss in small solute clearance and decreased glomerular filtration rate (GFR). Even modest degrees of acute renal failure not require dialysis treatment; increase the risk of death approximately five

---

Corresponding author: Nefissa Hussein Meky. E-mail: nefissa.meky@hotmail.com

fold (**Dennen *et al.*, 2010**). Acute kidney injury pathogenesis is complex, and promoting events may be completely different (ischemia or toxins are major factors that precipitate in the injury), but similar pathways may be involved in subsequent injury responses (**Hur *et al.*, 2013**).

Renal diseases are associated with a variety of haemopoietic changes. Anaemia parallels the degree of renal impairment and its most important cause is failure of renal erythropoietin secretion. Other factors include depressed red cell production and reduced red cell survival. Anemia is seen in patients with acute renal failure but the exact relationship between them remained unclear (**Hales *et al.*, 1994**).

Aminoglycosides antibiotics continue to be a main stay in clinical management of gram negative infection despite their nephrotoxicity. Gentamicin derived from gram-positive bacteria called *Micromonospora purpurea* present in soil and water having potential in treating aerobic gram-negative bacteria. Accumulation of gentamicin in proximal renal tubules may cause nephrotoxicity which leads to brush border network damage (**Whiting and Broun, 1996**). The nephrotoxicity involves renal free radical production and accumulation, consumption of antioxidant defense mechanisms, glomerular congestion, and acute tubular necrosis (**Abdel-Raheem *et al.*, 2009**), leading to diminished creatinine clearance and renal dysfunction. The pathological mechanisms also involve elevation of endothelin-1, upregulation of transforming growth factor-beta (TGF- $\beta$ ), significant increase in monocyte/macrophage infiltration into the renal cortex and medulla, augmentation of oxidative stress, and apoptosis and also necrosis (**Ali, 1995 and Bledsoe *et al.*, 2006**).

Oxidative stress has been recognized as an important contributory factor in a number of pathogenic processes including those affecting kidney leading to the possibility of utilizing the antioxidants for the prevention of nephrotoxicity (**Peres and Junior, 2013**). L-carnitine is biosynthesized mainly in the liver and kidney from the amino acids lysine and methionine. The kidney plays the major role in carnitine biosynthesis, excretion, and acylation, kidney contains all enzymes needed to form carnitine from trimethyl lysine in activities exceeding that of the liver (**Cibulka *et al.*, 2006**). L-carnitine is a compound widely distributed in nature and obtained primarily from the diet. It is involved in intermediary metabolism and is important to mammalian bioenergetic processes. It has been shown that L-carnitine plays an essential role in multiple primary functions (**Sirolli *et al.*, 2012**), and providing a protective effect against lipid peroxidation and oxidative stress (**Ye *et al.*, 2010**).

The major objective of this study was to investigate the possible ameliorating effect of L-carnitine against gentamicin-induced nephrotoxicity and some associated hematological changes in adult male albino rats and to exert the possible therapeutic role of L-carnitine depending on their antioxidant properties against the renal failure and its complication.

## **2. Materials and Methods**

### ***Drugs and Chemicals***

Gentamicin sulfate was obtained from Memphis Co., for Pharm. and Chem. Ind. (Cairo, Egypt). L-carnitine was supplied from Mepaco-Medifood Co. (Enshas Elraml, Egypt). All other chemicals used were of good quality and analytical grade.

### ***Animals***

Seventy adult Male albino rats weighing 110-125 gm were selected for this study. The animals were obtained from the animal house, Theodor Bilharz Research Institute (Giza, Egypt). The animals were housed in wire cages under good ventilation condition and adequate stable diet. At least a week before use, rats were acclimated to this environment with excess food pellets and water *ad-libitum* in order to ensure that all animals were in healthy condition. Experimental protocols were approved by scientific research practice committee at Theodor Bilharz Research Institute, Giza, Egypt.

### ***Experimental Protocol***

The animals were divided into two main groups:

**Group 1:** Rats in this group were injected with normal saline, intraperitoneally and served as a control (21 rats).

**Group 2:** Rats in this group were injected intraperitoneal with gentamicin (80 mg/ kg / day) for 10 days (**Silan *et al.*, 2007**) (49 rats).

After 10 days 7 rats from each group were sacrificed by decapitation. Blood samples were collected after decapitation of rats. Then the remaining of normal control rats were served as normal control rats group (Group 1) (14 rats), while the remaining 42 nephrotoxic rats will further subdivide in to the following subgroups:

**Subgroup 2** (control 2): Nephrotoxic rats receiving the corresponding placebo (14 rats).

**Subgroup 3:** Nephrotoxic rats in this group were injected intraperitoneal with low dose of L-carnitine (300 mg/kg/day) for 15 and 30 days (14 rats).

**Subgroup 4:** Nephrotoxic rats in this group were injected intraperitoneal with high dose of L-carnitine (600 mg/kg/day) for 15 and 30 days (14 rats).

At the end of each experiment period, 7 rats from each of the above groups were sacrificed by decapitation. Blood samples were collected after decapitation of rats.

One ml of blood was collected in sterile tube on potassium EDTA for hemogram by automated hematology analyzer ACT Differential (Beckman Coulter, France). The remaining blood sample were collected into tube and allowed to clot at room temperature. Thereafter, serum was separated by centrifugation at 1200\_g for 15 min at 4 °C for determination of serum urea, creatinine and total protein by Hitachi 736, Hitachi, Japan. The rest of the sera were aliquoted, stored and kept frozen at -70°. Determination of sodium and potassium analysis was accomplished by emission flame photometry after suitable dilution as described by **Dean (1960)**.

#### ***Determination of serum $\beta_2$ -microglobulin:***

Serum  $\beta_2$ -microglobulin was determined using the double-sandwich ELISA technique using commercial kits MyBioSource Co., USA as described by **Cunningham et al. (1973)**.

#### ***Evaluation of Erythrocyte Osmotic Fragility:***

In vitro erythrocyte osmotic fragility was evaluated in all the rats in each group using the method described by **Dacie and Lewis, (1995)**, using different amounts of sodium chloride (pH 7.4) from 0.0, 0.1, 0.3, 0.5, 0.7 and 0.9 g/L of distilled water. Briefly, freshly obtained whole blood from each rat was pipetted into the test tubes containing varying concentration of NaCl and then followed by careful, gentle mixing and incubation for 30 minutes at room temperature, 26-28°C. The samples were then centrifuged at 600 g for 10 minutes. The supernatant was transferred into a glass cuvette and the absorbance of the supernatant measured colorimetrically with at a wave length of 540 nm. The percent haemolysis for each sample was calculated based on the formula;

$$\text{Percent haemolysis} = \frac{\text{Optical density of test solution} \times 100}{\text{Optical density of standard solution}}$$

#### **Determination of Oxidative Stress Biomarkers (Redox data):-**

##### ***1-Determination of total antioxidant status (TAS):***

In this kit the reduced ABTS (2,2'-azinobis (3-ethylbenzothiazoline-6-sulfonate) molecule is oxidized to ABTS<sup>+</sup>, using hydrogen peroxide alone in an acidic medium. In the acetate buffer solution the concentrated (dark blue-green) ABTS<sup>+</sup> molecules remain more stable for a long time. While it is diluted with a more concentrated

acetate buffer solution at high pH, the color is spontaneously and slowly bleached. Antioxidants present in the sample accelerate the bleaching rate to a degree proportional to their concentrations. The bleaching rate is inversely related to TAS of the sample (Erel, 2004).

### ***2-Determination of total oxidant status (TOS):***

In this kit oxidants present in the sample oxidize the ferrous ion–o-dianisidine complex to ferric ions. The oxidation reaction is enhanced by glycerol molecules, which are abundant in the reaction medium. The ferric ions make a colored complex with xylenol orange in an acidic medium. The colour intensity, which can be measured by spectrophotometric, is related to the total quantity of oxidant molecules in the sample (Erel, 2005).

### **Determination of iron metabolism:**

#### ***1- Determination of serum iron (Fe):***

Serum Fe was determined using kits from Bio-Labo. Co., France. according to the method described by Hennesy *et al.* (1984).

#### ***2- Determination of serum ferritin:***

Serum ferritin was determined using the ELISA (sandwich enzyme-linked immune sorbent assay) using commercial kits Li Star Fish, Italy, described by Sukanya *et al.* (1981).

#### ***3- Determination of total iron binding capacity (TIBC):***

Serum TIBC was determined using kits from Bio-Labo. Co., France. according to the method described by Tietz *et al.* (1999).

### **3.Results and discussion**

The serious complications resulting from gentamicin treatment are shown in table (1).

**Table (1): Effects of gentamicin**

<b>Parameters</b>	<b>Normal control</b>	<b>Nephrotoxic rats</b>	<b>%</b>
<b>Urea (mg/dl)</b>	25.840±0.770	79.030±1.340**	205.84
<b>Creatinine (mg/dl)</b>	0.550±0.070	2.270±0.410**	312.73
<b>Total protein (g/dl)</b>	7.120±0.380	5.770±0.370**	-18.96
<b>β2-microglobulin (ng/ml)</b>	2.350±0.220	29.780±1.790**	1167.23
<b>Na (meq/L)</b>	134.180±1.270	121.690±1.330**	-9.31
<b>K (meq/L)</b>	4.220±0.120	5.670±0.280**	34.36
<b>Osmotic fragility initial (%)</b>	0.520±0.101	0.750±0.070**	44.23
<b>Osmotic fragility complete (%)</b>	0.370±0.180	0.530±0.110**	43.24
<b>RBCs (x10<sup>12</sup>/L)</b>	7.850±1.230	5.780±0.490**	-26.37
<b>Hb concentration (g/dl)</b>	15.001±1.620	11.350±0.520**	-24.34
<b>TAS (mmol Trolox Equiv./L)</b>	4.160±0.190	2.520±0.180**	-39.42
<b>TOS (μmol H<sub>2</sub>O<sub>2</sub> Equiv./L)</b>	12.080±0.860	17.580±0.130**	45.53
<b>Fe (μg/dL)</b>	129.001±0.316	131.250±0.371*	1.74
<b>Ferritin (ng/mL)</b>	65.200±1.370	70.680±1.520*	8.40
<b>TIBC (μg/dL)</b>	391.801±0.374	398.001±1.414*	1.58

- Values are expressed as means ± S.E.

- %: The percentage of change of nephrotoxic rats group compared to normal control in the same row

\*:Significant difference compared to the control group at P<0.05

\*\* : Significant difference compared to the control group at P<0.001

The effects of low and high dose of L-carnitine on nephrotoxic rats are presented in tables 2, 3 and 4.

**Table (2): Effects of L-carnitine on kidney function.**

<b>Groups</b> <b>Parameters</b>	<b>Normal control</b>	<b>Nephrotoxic rats</b>	<b>Nephrotoxic rats + low dose of L- carnitine</b>	<b>Nephrotoxic rats + high dose of L- carnitine</b>
<b><u>Urea (mg/dl)</u></b>				
<b>15 days</b>	26.001 ± 0.440 <sup>A</sup> <sub>a</sub>	74.600± 1.330 <sup>B</sup> <sub>a</sub>	51.700± 1.210 <sup>C</sup> <sub>a</sub>	40.300 ± 1.220 <sup>D</sup> <sub>a</sub>
<b>30 days</b>	25.001 ± 0.580 <sup>A</sup> <sub>b</sub>	68.540±1.520 <sup>B</sup> <sub>b</sub>	39.700 ± 1.190 <sup>C</sup> <sub>b</sub>	30.400 ± 1.330 <sup>D</sup> <sub>b</sub>
<b><u>Creatinine (mg/dl)</u></b>				
<b>15 days</b>	0.520 ± 0.090 <sup>A</sup> <sub>a</sub>	1.990 ± 0.330 <sup>B</sup> <sub>a</sub>	1.310 ± 0.210 <sup>C</sup> <sub>a</sub>	0.790 ± 0.150 <sup>D</sup> <sub>a</sub>
<b>30 days</b>	0.500 ± 0.130 <sup>A</sup> <sub>b</sub>	1.710 ± 0.240 <sup>B</sup> <sub>b</sub>	0.830 ± 0.120 <sup>C</sup> <sub>b</sub>	0.730 ± 0.110 <sup>D</sup> <sub>b</sub>
<b><u>Total protein (g/dl)</u></b>				
<b>15 days</b>	6.990 ± 0.580 <sup>A</sup> <sub>a</sub>	5.870±0.370 <sup>B</sup> <sub>a</sub>	6.210±0.510 <sup>C</sup> <sub>a</sub>	6.710±0.330 <sup>D</sup> <sub>a</sub>
<b>30 days</b>	7.100 ± 0.810 <sup>A</sup> <sub>a</sub>	6.050±0.420 <sup>B</sup> <sub>b</sub>	6.730±0.650 <sup>C</sup> <sub>b</sub>	6.950±0.340 <sup>A</sup> <sub>b</sub>
<b><u>β<sub>2</sub>-microglobulin (ng/ml)</u></b>				
<b>15 days</b>	2.340 ± 0.480 <sup>A</sup> <sub>a</sub>	28.720±1.130 <sup>B</sup> <sub>a</sub>	19.350±1.130 <sup>C</sup> <sub>a</sub>	8.900±1.330 <sup>D</sup> <sub>a</sub>
<b>30 days</b>	2.350 ± 0.720 <sup>A</sup> <sub>a</sub>	27.500±1.320 <sup>B</sup> <sub>b</sub>	8.500±1.270 <sup>C</sup> <sub>b</sub>	3.100±1.150 <sup>D</sup> <sub>b</sub>
<b><u>Na (meq/L)</u></b>				
<b>15 days</b>	135.600 ± 1.260 <sup>A</sup> <sub>a</sub>	124.650±1.530 <sup>B</sup> <sub>a</sub>	126.200±1.320 <sup>B</sup> <sub>a</sub>	130.370±1.480 <sup>C</sup> <sub>a</sub>
<b>30 days</b>	136.010 ± 1.180 <sup>A</sup> <sub>a</sub>	126.500±1.420 <sup>B</sup> <sub>a</sub>	131.390±1.380 <sup>C</sup> <sub>b</sub>	134.360±1.220 <sup>A</sup> <sub>b</sub>
<b><u>K (meq/L)</u></b>				
<b>15 days</b>	4.190 ± 0.330 <sup>A</sup> <sub>a</sub>	5.490±0.330 <sup>B</sup> <sub>a</sub>	5.060±0.170 <sup>C</sup> <sub>a</sub>	4.400±0.310 <sup>D</sup> <sub>a</sub>
<b>30 days</b>	4.210 ± 0.250 <sup>A</sup> <sub>a</sub>	5.300±0.290 <sup>B</sup> <sub>b</sub>	4.390±0.310 <sup>C</sup> <sub>b</sub>	4.160±0.130 <sup>A</sup> <sub>b</sub>

-Data were represented as mean ± standard error.

-A, B, C, D: means bearing different superscripts within the same row are differ significantly (P<0.05).

-a, b: means bearing different superscripts within the same column are differ significantly (P<0.05).

**Table (3): Effects of L-carnitine on redox data, RBCs, Hb and osmotic fragility**

<b>Groups</b>	<b>Normal control</b>	<b>Nephrotoxic rats</b>	<b>Nephrotoxic rats + low dose of L-carnitine</b>	<b>Nephrotoxic rats + high dose of L-carnitine</b>
<b>Parameters</b>				
<b><u>TAS</u> (mmol Trolox Equiv./L )</b>				
<b>15 days</b>	4.150 ± 0.360 <sup>A</sup> <sub>a</sub>	2.720±0.210 <sup>B</sup> <sub>a</sub>	3.490±0.390 <sup>C</sup> <sub>a</sub>	3.840±0.190 <sup>D</sup> <sub>a</sub>
<b>30 days</b>	4.170 ± 0.180 <sup>A</sup> <sub>a</sub>	2.880±0.340 <sup>B</sup> <sub>b</sub>	3.890±0.360 <sup>C</sup> <sub>b</sub>	4.040±0.440 <sup>D</sup> <sub>b</sub>
<b><u>TOS</u> (µmol H<sub>2</sub>O<sub>2</sub> Equiv./L)</b>				
<b>15 days</b>	11.900 ± 0.330 <sup>A</sup> <sub>a</sub>	17.200±0.630 <sup>B</sup> <sub>a</sub>	14.001±0.630 <sup>C</sup> <sub>a</sub>	12.880±0.660 <sup>D</sup> <sub>a</sub>
<b>30 days</b>	11.830 ± 0.580 <sup>A</sup> <sub>a</sub>	17.020±0.110 <sup>B</sup> <sub>a</sub>	12.560±0.860 <sup>C</sup> <sub>b</sub>	11.860±0.730 <sup>A</sup> <sub>b</sub>
<b><u>RBCs</u> ( X10<sup>12</sup>/L )</b>				
<b>15 days</b>	7.770 ± 0.880 <sup>A</sup> <sub>a</sub>	5.900±0.160 <sup>B</sup> <sub>a</sub>	6.790±0.330 <sup>C</sup> <sub>a</sub>	7.050±0.510 <sup>D</sup> <sub>a</sub>
<b>30 days</b>	7.900 ± 0.580 <sup>A</sup> <sub>a</sub>	6.100±0.410 <sup>B</sup> <sub>b</sub>	7.150±0.420 <sup>C</sup> <sub>b</sub>	7.570±0.830 <sup>D</sup> <sub>b</sub>
<b><u>Hb concentration</u> (g/dl)</b>				
<b>15 days</b>	14.870 ± 1.330 <sup>A</sup> <sub>a</sub>	11.440±0.480 <sup>B</sup> <sub>a</sub>	12.860±0.190 <sup>C</sup> <sub>a</sub>	14.180±0.510 <sup>D</sup> <sub>a</sub>
<b>30 days</b>	15.030 ± 1.880 <sup>A</sup> <sub>a</sub>	11.730±0.430 <sup>B</sup> <sub>a</sub>	14.090±0.610 <sup>C</sup> <sub>b</sub>	14.640±0.650 <sup>A</sup> <sub>b</sub>
<b><u>Osmotic fragility initial</u> (%)</b>				
<b>15 days</b>	0.530 ± 0.020 <sup>A</sup> <sub>a</sub>	0.740±0.040 <sup>B</sup> <sub>a</sub>	0.640±0.010 <sup>C</sup> <sub>a</sub>	0.540±0.010 <sup>D</sup> <sub>a</sub>
<b>30 days</b>	0.520±0.020 <sup>A</sup> <sub>a</sub>	0.710±0.030 <sup>B</sup> <sub>b</sub>	0.540±0.010 <sup>C</sup> <sub>b</sub>	0.500±0.030 <sup>A</sup> <sub>b</sub>
<b><u>Osmotic fragility complete</u> (%)</b>				
<b>15 days</b>	0.370 ± 0.020 <sup>A</sup> <sub>a</sub>	0.510±0.110 <sup>B</sup> <sub>a</sub>	0.440±0.020 <sup>C</sup> <sub>a</sub>	0.380±0.010 <sup>D</sup> <sub>a</sub>
<b>30 days</b>	0.380± 0.020 <sup>A</sup> <sub>a</sub>	0.500±0.050 <sup>B</sup> <sub>a</sub>	0.390±0.010 <sup>C</sup> <sub>b</sub>	0.360±0.010 <sup>A</sup> <sub>b</sub>

-Data were represented as mean ± standard error.

-A, B, C, D: means bearing different superscripts within the same row are differ significantly (P<0.05).

-a, b: means bearing different superscripts within the same column are differ significantly (P<0.05).

**Table (4): Effects of L-carnitine on iron metabolism**

Groups Parameters	Normal control	Nephrotoxic rats	Nephrotoxic rats + low dose of L- carnitine	Nephrotoxic rats + high dose of L- carnitine
<b>Ferritin (ng/mL)</b>				
15 days	66.001 ± 0.580 <sup>A</sup> <sub>a</sub>	70.800±0.580 <sup>B</sup> <sub>a</sub>	68.630±0.190 <sup>C</sup> <sub>a</sub>	68.370±0.190 <sup>C</sup> <sub>a</sub>
30 days	65.500± 0.810 <sup>A</sup> <sub>a</sub>	69.500±0.630 <sup>B</sup> <sub>a</sub>	67.120±0.390 <sup>C</sup> <sub>a</sub>	65.830±0.390 <sup>A</sup> <sub>b</sub>
<b>Fe (µg/dL)</b>				
15 days	128.666 ± 0.166 <sup>A</sup> <sub>a</sub>	130.633±0.185 <sup>B</sup> <sub>a</sub>	129.710±0.033 <sup>C</sup> <sub>a</sub>	128.270±0.194 <sup>A</sup> <sub>a</sub>
30 days	128.500± 0.577 <sup>A</sup> <sub>a</sub>	129.800±0.707 <sup>B</sup> <sub>a</sub>	128.698±0.265 <sup>C</sup> <sub>b</sub>	128.377±0.292 <sup>A</sup> <sub>a</sub>
<b>TIBC (µg/dL)</b>				
15 days	391.333 ± 0.333 <sup>A</sup> <sub>a</sub>	396.733±0.968 <sup>B</sup> <sub>a</sub>	395.450±0.165 <sup>C</sup> <sub>a</sub>	394.266±0.194 <sup>C</sup> <sub>a</sub>
30 days	392.000 ± 0.577 <sup>A</sup> <sub>a</sub>	395.600±0.815 <sup>B</sup> <sub>a</sub>	393.500±0.500 <sup>C</sup> <sub>b</sub>	392.888±0.351 <sup>A</sup> <sub>b</sub>

Data were represented as mean ± standard error.

-A, B, C, D: means bearing different superscripts within the same row are differ significantly (P<0.05).

-a,b: means bearing different superscripts within the same column are differ significantly (P<0.05).

The correlation between L-carnitine and different studied parameters are presented in table 5

**Table (5): correlation between L-carnitine and different studied parameters**

Correlations	low dose of L-carnitine Correlation coefficients	high dose of L-carnitine Correlation coefficients
L-carnitine vs urea	-0.96**	-0.98**
L-carnitine vs creatinine	-0.99**	-0.91**
L-carnitine vs total protein	0.96**	0.96**
L-carnitine vs β <sub>2</sub> -microglobulin	-0.99**	-0.95**
L-carnitine vs Na	0.96**	0.99**
L-carnitine vs K	-0.99**	-0.95**
L-carnitine vs osmotic fragility initial	-1.00**	-0.91**
L-carnitine vs osmotic fragility complete	-0.99**	-0.91**
L-carnitine vs RBCs	0.96**	0.97**
L-carnitine vs Hb concentration	0.99**	0.94**
L-carnitine vs TAS	0.98**	0.92**
L-carnitine vs TOS	-0.96**	-0.92**
L-carnitine vs Fe	-0.98**	-0.95**
L-carnitine vs Ferritin	-0.91**	-0.99**
L-carnitine vs TIBC	-0.99**	-0.94**

\*\* Correlation is significant at the 0.001 level

Gentamicin-induced nephropathy is a limiting factor for its clinical usage. Results from many studies (**Pedraza-Chaverri et al., 2004**) have shown that gentamicin produced an elevation in the concentrations of biochemical indicators of kidney function such as serum urea, creatinine and total protein excretion in urine and elevation in  $\beta_2$ -microglobulin concentration (**Gonick, 2008**). Consistent with the data from these studies we observed in our study that urinary excretion of total protein was increased after gentamicin injection indicating tubular damage. On the other hand, urea and serum creatinine levels were augmented indicating glomerular damage. Damage to the proximal tubules leads to decreased reabsorptive capability and increased  $\beta_2$ -microglobulin concentrations (**Gonick, 2008**). Also, **Adeyemi et al. (2001)** reported that, appearance of  $\beta_2$ -microglobulin in the urine depends on plasma  $\beta_2$ -microglobulin elevation exceeding its renal reabsorptive threshold of 5mg/l and/or from proximal tubular damage. Serum electrolytes were disturbed significantly in gentamicin treated rats as compared with normal control rats. Gentamicin may cause  $\text{Na}^+$  loss due to hyper dynamic circulation which in turn leads to the observed increased in serum  $\text{K}^+$  level that observed in this study. These results are in agreement with **Lobetti and Joubert, (2000)** and **Saleh (2014)**. Moreover, these results are in harmony with **Heibashy et al.(2010)**. The last author demonstrated that, lower value of  $\text{Na}^+$  indicates inability of kidney to conserve  $\text{Na}^+$  and chloride. Haemodilution may be involved in the fall of  $\text{Na}^+$  value *via* excess of water intake and or increased production of endogenous water. In turn, the reversed increases of  $\text{K}^+$  appeared may be due to reduced excretion of  $\text{K}^+$  aggravated by leakage of intracellular  $\text{K}^+$  in to blood stream as a results of gentamicin induced lesions in renal tubular epithelium.

The toxicity of gentamicin is believed to be related to the generation of reactive oxygen species (ROS) in the kidney (**Martinez-Salgado et al., 2004**). The results of present study revealed significant increase in TOS and decrease in TAS in nephrotoxic group compared to normal control group. These results are in harmony with studies of **Hozayen et al. (2011)** who found that gentamicin administration to rats enhances the production of hydrogen peroxide in renal cortical mitochondria as a result of the increase in the production of superoxide anions. Superoxide anion and hydrogen peroxide may interact to form a reactive and unstable radical, namely a hydroxyl radical (**Lobo et al., 2010**). This radical is formed by the reaction between hydrogen peroxide and  $\text{Fe}^{2+}$  (**Kocha et al., 1997**).  $\text{Fe}^{2+}$  appeared to play an important role in the production of reactive oxygen radicals in gentamicin nephrotoxicity and when oxygen radicals begin to accumulate; renal cells exhibit a defensive mechanism by using various antioxidant enzymes; such as (Catalase) CAT, (Superoxide dismutase) SOD and (Glutathione peroxidase) GPx activities (**Wang et al., 2005**). Reduced activity of one or more antioxidant systems, due to the direct toxic effect of gentamicin or volume depletion due to gentamicin administration, leads to an increase in lipid peroxidation. The decreased amount of intracellular GSH and

the accumulation of hydrogen peroxide and hydroxyl radicals are the triggering factors in gentamicin nephrotoxicity (**Erdem *et al.*, 2000**). Moreover, **Yaman and Balikci *et al.* (2010)** reported a highly significant decrease in SOD and CAT activity after gentamicin administration. **Parlakpinar *et al.* (2005)** showed that gentamicin suppresses antioxidant defense enzymes and increases lipid peroxidation in the kidney. This gives rise to membrane lipid damage and initiation of autocatalytic reactions. The damage in plasma membrane results in loss of osmotic balance and intracellular calcium levels increase. **Yazar *et al.* (2003)** demonstrated that gentamicin administration to normal rats caused severe damage to renal tissues most likely by ROS mediated mechanism as evident by decreased activities of above antioxidant enzymes and total SH levels that led to increased lipid peroxidation. Also **Banday *et al.* (2008)** reported a highly significant increase of lipid peroxidation activity.

Hematological constituents usually reflect the physiological responsiveness of the animal to its external and internal environments and this is serving as a veritable tool for monitoring animal health. Hematological profile in animals is an important indicator of physiological or pathophysiological status of the body (**Elsayed, *et al.*, 2014**). Our data showed that anaemia has been observed following administration of gentamicin in albino rats. Gentamicin induced a highly significant decrease in Hb concentration and RBCs. This results are in line with data obtained by **Debska-Slizien *et al.*, (2011)** and **El-Maddawy (2014)**. Several mechanisms could contribute to the anemia observed after gentamicin induced renal failure. Erythropoietin (Epo) is the major physiological regulator of erythropoiesis. The primary site of Epo is thought to be the renal peritubular cells. It has been reported that regulation to Epo production is related to proximal tubular function. Therefore, one of the major causes of the anaemia induced by gentamicin treatment is Epo deficiency following injury to the kidney (**Naeshiro *et al.*, 1997**). **Nagano *et al.* (1990)** reported that a gentamicin-treated rat is a useful and convenient anaemic model and recombinant human erythropoietin (r-HuEPO) is useful for treatment of anaemia in acute renal failure. Anemia may also results from hemodilution, extra vascular hemolysis as well as from toxic dyshematopoiesis (**Elyazji and Abdel-Aziz, 2013**). Anaemia may be the result of lipoperoxidative changes in erythrocyte membrane (**Ambali *et al.*, 2010**).

Erythrocytes have been used extensively as a model system for investigating mechanisms of oxidative stress since these cells, lacking protein synthesis machinery and represent a simplified model (**Battistelli *et al.*, 2005**). In addition, The RBC is

vulnerable to lipoperoxidative changes because of its direct association with molecular oxygen, high content of metal ions catalyzing oxidative reaction and availability of high amount of Polyunsaturated fatty acids (PUFA), which are susceptible to lipid peroxidation (**Wadhwa et al., 2012**).

Oxidative stress which results from the generation of free radicals and alteration in free radical scavenging system is one of the complex factors that determine the integrity of the erythrocyte (**Uzum et al., 2006**). **Chidiebere et al. (2011)** showed that the destruction of RBCs is postulated to occur by either membrane oxidation or Hb denaturation. The oxidative modification of the erythrocyte membrane has been shown to increase the fragility of RBC. In our study the increase in the erythrocyte osmotic fragility in nephrotoxic rats confirmed the observation that this can be used as indirect method of evaluating lipid peroxidation in animals. Process of lipid peroxidation decreases hydrophobic characteristic of bilayer membrane of erythrocyte altering affinity and interaction of protein and lipids, thereby impairing the functioning and homeostasis of erythrocyte membranes (**Ambali et al., 2010**). Plasma levels of lipid peroxidation products correlate with the severity of renal anaemia (**Horl, 2002**). Generation of oxygen free radicals may result in cross-linking within membrane proteins and/ or between membrane proteins and Hb. Protein degradation was found to be increased in RBC exposed to oxygen free radicals, with RBC morphological changes accompanying these structural alterations; echinocyte formation is a characteristic morphological change due to oxidant damage (**Kusmic et al., 2000**). Mechanical stability of RBC membranes may also be influenced by oxidant attack, and instability may result from oxidative alterations in certain membrane skeletal proteins (**Lin and Beiyi, 2008**). It has been previously reported that oxidants can alter surface characteristics of RBC (**Shi and Pamer, 2011**), by a decreased cytoskeletal protein content and production of high-molecular-weight proteins, which can lead to abnormalities in erythrocyte shape and rheologic properties (**Battistelli et al., 2005**). Additionally, oxidative damage may affect the transport processes through the RBC membrane, affecting the cell geometry and cytosolic viscosity, accompanied by the alterations in the cytosolic concentration of cations. Calcium homeostasis is an important determinant of normal RBC deformability; increased cytosolic calcium concentration leads to impaired RBC deformability (**Toptas et al., 2006**).

The data obtained from present study showed that gentamicin induced a significant increase in serum iron, ferritin and TIBC. In vivo, most of the iron is bound to heme and non heme proteins and does not directly catalyze the generation of the hydroxyl radical (**Baliga et al., 1998**). The in vitro and in vivo studies indicate

enhanced generation of hydrogen peroxide and release of iron in response to gentamicin. Based on the ability of superoxide to release iron from the iron-storage protein ferritin (which normally provides a secure mean for iron storage in the inert form), ferritin has been suggested as a possible source of iron for the generation of powerful oxidant species. Ferritin is an acute-phase reactant, its synthesis is up-regulated by infection or inflammation (**Pourabbas *et al.*, 2013 and El-Khatib, 2009**). Similar increase in serum ferritin was detected in patients with acute renal failure (**Gulcelik and Kayatas, 2002 and Branten *et al.*, 2004**). Moreover, Gentamicin was shown to chelate mitochondrial iron mediated by hydrogen peroxide forming iron-gentamicin complex which is a potent catalyst of free radical formation capable of inhibiting mitochondrial respiration causing cell death (**El-Maddawy, 2014**). In addition, Fe levels increased in serum as a result of increased hemolysis of RBCs this in line with **Crook, (2012)** who demonstrated that in hemolysis condition ferritin and Fe levels increased. TIBC increased to bind Fe which liberated from RBCs destructed. Iron has a major role in the initiation and propagation of lipid peroxidation, either by catalyzing the conversion of primary oxygen radicals to hydroxyl radicals or forming a perferryl iron. In addition, iron can directly catalyze lipid peroxidation, the oxidative reaction of polyunsaturated lipids, by removing hydrogen atoms from PUFA in the lipid bilayers of organelle membranes (**Shah *et al.*, 2007**). Multiple independent pathways exist which converge in the increase of ferritin synthesis in response to various forms of oxidative insult. Ferritin, with its ability to oxidize and sequester intracellular iron in an internal mineral core, limits the levels of catalytically available iron, owing to the generation of free radicals, as a critical cytoprotective protein that constitutes an integral part of the antioxidant response (**Traina, 2011**).

The knowledge of the mechanisms responsible for aminoglycosides-induced renal damage has prompted the development of potential strategies to prevent its nephrotoxicity (**Reisfeld *et al.*, 2011**). The most used strategies to prevent aminoglycosides toxicity have been: a) blocking aminoglycosides binding to membranes and aminoglycosides uptake; b) preventing phospholipidosis, c) reducing oxidative stress, d) antagonizing vasoconstrictor effects; d) preventing inflammation (**Servais *et al.*, 2008**). Recent studies have shown that natural antioxidants obtained from different alternative systems of medicine display a wide range of biological activities. Various alternatives possessing antioxidant properties have been used in order to minimize gentamicin induced oxidative stress in animal models (**Khan *et al.*, 2011**).

In the present study L-carnitine was administered in low dose (300 mg/kg/day) and high dose (600 mg/kg/day) in order to provide some assurance that if no ameliorating effect of L-carnitine was identified, the lack of effect could not be ascribed to an inadequately small dose. Data revealed significant improvement in both urea and creatinine level which was dependently related to L-carnitine doses. Our data was in agreement with **Ustundag *et al.* (2009)** and **Gebaly *et al.* (2012)** who reported that this improvement seem to presumably be due to the amelioration of gentamicin induced oxidative injury to the tubular system and significant increase in total protein. The mechanism by which this antioxidant performed its action may be due to its membrane stabilizing effect and ROS scavengers. This is in agreement with the results of **Duranay *et al.* (2006)**. The last authors reported that the increase of total protein might be caused by improved anabolic effects or anti-inflammatory activities of L-carnitine. In kidneys, L-carnitine decreased the severity of renal cortical proximal tubular necrosis and improved renal function in rats with gentamicin-induced or doxorubicin-induced renal injury (**Boonsanit *et al.*, 2006**).  $\beta$ 2-microglobulin were corrected significantly in current study. The improvement in serum  $\beta$ 2-microglobulin dependently related to L-carnitine doses. This is in agreement with the results of **Ustundag *et al.* (2009)**. The last authors reported that improvement seem to presumably be due to the amelioration of gentamicin induced oxidative injury to the tubular system. In current study, L-carnitine low and high dose induced a great improvement in serum  $\text{Na}^+$  and  $\text{K}^+$  levels. The improvement in serum  $\text{Na}^+$  and  $\text{K}^+$  levels dependently related to L-carnitine dose, this improvement might be due to L-carnitine had protective effect on lipid peroxidation by reducing formation of hydrogen peroxides and MDA, and it improved antioxidant status in rats. Moreover, it increased free radical scavenging from the cellular sites (**Sener *et al.*, 2004**).

Data of the present study revealed significant increase in TAS and decreases in TOS in rats treated with both low and high dose of L-carnitine. L-carnitine inhibits superoxide radicals, and reduces lipid peroxidation catalyzed by hydrogen peroxide. It is also proposed that L-carnitine can reduce the production of hydroxyl radicals generated by iron, because of its iron-chelating activity (**Vanella *et al.*, 2000**). **Boonsanit *et al.* (2006)** also reported improvement of kidney functions and the correction of decreased level of oxidative stress enzymes in the form of SOD, CAT and Serum GSH by the use of L-carnitine. **Mansour (2013)** also showed that L-carnitine improved endothelial responses by decreasing ROS production and increasing nitric oxide availability. L-carnitine also could help the cells to repair single-strand breaks induced in DNA and to protect it from oxygen free radicals (**Alzahrani, 2011**).

L-carnitine maintains membrane stability; this has been shown most clearly in erythrocytes. Rats treated with L-carnitine in the present study showed significantly increase in Hb concentration and RBCs. Effect of L-carnitine on Hb content was parallel to its action on RBCs count. Moreover, data in present study revealed that treatment with L-carnitine ameliorated the increase in erythrocyte fragility following gentamicin treatment. Our results were in accordance with **Horl (2002); Malaguarnera *et al.* (2011) and El-Maddawy (2014)** who reported that treatment with L-carnitine improved hematological parameters due to its antioxidant properties that enhanced hematopoiesis. **Nikolaos *et al.* (2000) and Nand *et al.* (2008)** also noticed similar results in hemodialysis patients treated with L-carnitine supplementation. L-carnitine plays an important role in the cellular metabolism by participating to the structural units of erythrocyte membrane (lipids and proteins such as spectrin and actin) and to the mitochondrial oxidative degradation of long chain fatty acids (**Karadeniz *et al.*, 2008**). L-carnitine was found to protects erythrocytes from oxidative stress, prevents lipid peroxidation and stabilizes the cell membrane, raises RBC osmotic resistance, reduces deformability of RBC, increasing the life span of RBCs and was found to inhibit apoptosis in different diseases (**Ragab and Mahfouz, 2010 and Kudoh *et al.*, 2014**). Moreover, **Chidiebere *et al.* (2011)** reported that L-carnitine increases the action of EPO on bone marrow. The activity of  $\text{Na}^+-\text{K}^+$ -ATPase in erythrocytes is inhibited by the addition of uraemic plasma (**Ambali *et al.*, 2010**), which reduces the number of pump sites, particularly in young erythrocytes. L-carnitine has a key role in  $\text{Na}^+-\text{K}^+$  pump activity, instrumental in the maintenance of the biconcave discoid shape of erythrocytes. Circulating free fatty acids are endogenous inhibitors of the  $\text{Na}^+-\text{K}^+$ -ATPase. L-carnitine increases delivery of free fatty acid to the mitochondria for oxidation and as a result the plasma concentration of free fatty acids decreases and the inhibition of the  $\text{Na}^+-\text{K}^+$ -ATPase was reversed (**Uchendu *et al.*, 2011**). Indeed the direct L-carnitine addition to whole blood in vitro delayed haemolysis (**Karadeniz *et al.*, 2008**).

The noticed ameliorating effect of L-carnitine on RBCs count, RBCs membrane stability and free radical scavengers may explain the significant decrease in serum ferritin, serum Fe and TIBC levels detected in the present study. This is in agreement with **Matsumoto *et al.* (2001)** who reported that significant decrease in Fe may related to that L-carnitine had beneficial effects on stabilized cellular membranes prolongs their lives and raises RBC osmotic resistance. Moreover, **Traina (2011)** reported that L-carnitine down regulates ferritin-H gene expression. L-carnitine suppressed hydroxyl radical production probably by chelating the iron required for the generation of hydroxyl radicals. Furthermore, the preventive effect of L-carnitine on

the formation of ROS due to the xanthine /Xo system has been demonstrated (Mohamed and Farghaly, 2009). L-carnitine exerts antioxidant effect and reverses iron-induced oxidative stress in human fibroblast. It is possible that L-carnitine might reduce available iron, by reducing ferritin expression (Traina, 2011).

#### 4. Conclusion

The present study revealed the nephrotoxic effects of gentamicin and its hazardous influence on RBCs count and RBCs membrane stability. The use of L-carnitine in combination with gentamicin minimized its toxicity as revealed from decreasing urinary excretion of total protein, serum urea, creatinine and  $\beta$ 2-microglobulin levels. In addition, L-carnitine had been proved to have an ameliorating effect the on gentamicin-induced anaemia and enhanced erythrocyte membrane stability and RBCs osmotic resistance. Oxidative stress reactions, ROS and release of iron may be one of the mechanisms of gentamicin-induced nephrotoxicity. The ameliorative effect of L-carnitine against gentamicin-induced toxicity may be at least in part due to its antioxidant and free radicals scavenger properties and may indicate the utility of adjuvant L-carnitine treatment for renal toxicity and anemia management in gentamicin treated patients.

#### 5. References:

- Abdel-Raheem, I.T.; Abdel-Ghany, A.A. and Mohamed, G. A.** ,Protective effect of quercetin against gentamicin-induced nephrotoxicity in rats. *Biological and Pharmaceutical Bulletin*; 32(1): 61–67(2009).
- Adeyemi, E.O.; Obineche, E.N.; Abdulle, A.Sh. and Osman, A.R.,** Evaluation of plasma  $\beta$ 2-microglobulin in patients with the nephrotic syndrome. *Saudi Journal of Kidney Diseases and Transplantation*; 12 (2): 151-156(2001).
- Ali, B. H.,** Gentamicin nephrotoxicity in humans and animals: some recent research. *General Pharmacology*; 26 (7):1477–1487(1995).
- Alzahrani, H.A.S.,** Protective effect of L-carnitine against acrylamide-induced DNA damage in somatic and germ cells of mice. *Saudi Journal of Biological Sciences*; 18: 29–36(2011).
- Ambali, S. F.; Abubakar, A.T.; Shittu, M.; Yaqub, L.S.; Anafi, S.B. and Abdullahi, A.,** Chlorpyrifos-induced alteration of hematological parameters in *wistar* rats: Ameliorative effect of zinc. *Research Journal of Environmental Toxicology*; 4(2): 55-66(2010).

- Baliga, R.; Zhang, Z.; Baliga, M.; Ueda, N. and Shah, S.V.,** Role of cytochrome P-450 as a source of catalytic iron in cisplatin-induced nephrotoxicity. *Kidney International*; 54: 1562–1569(1998).
- Banday, A.A.; Farooq, N.; Priyamvada, S.; Yusufi, A.N. and Khan F.,** Time dependent effects of gentamicin on the enzymes of carbohydrate metabolism, brush border membrane and oxidative stress in rat kidney tissues. *Life Sciences Journal*; 82(9-10):450-459(2008).
- Battistelli, M.; De Sanctis, R.; De Bellis, R.; Cucchiari, L.; Dachà, M. and Gobbi, P.,** Rhodiola rosea as antioxidant in red blood cells: ultrastructural and hemolytic behaviour. *European Journal of Histochemistry*; 49(3): 243-254(2005).
- Bledsoe, G.; Crickman, S.; Mao, J.; Xia, C.F.; Murakami, H.; Chao, L. and Chao, J.,** Kallikrein/kinin protects against gentamicin-induced nephrotoxicity by inhibition of inflammation and apoptosis. *Nephrology Dialysis Transplantation*; 21(3): 624–633(2006).
- Boonsanit, D.; Kanchanapangka, S. and Buranakarl, C.,** L-carnitine ameliorates doxorubicin-induced nephrotic syndrome in rats. *Nephrology Journal*; 11(4):313-320(2006).
- Branten, A.J.; Swinkels, D.W.; Klasen, I.S. and Wetzels, J.F.,** Serum ferritin levels are increased in patients with glomerular diseases and proteinuria. *Journal of Nephrology, Dialysis and Transplantation*; 19(11):2754-2760(2004).
- Chidiebere, U.; Ambali, S.F.; Ayo, J.O. and Eseivo, K.A.N.,** Acetyl-L-carnitine attenuates haemotoxicity induced by subacute chlorpyrifos exposure in wistar rats. *Der Pharmacia Lettre Journal*; 3(2): 292-303(2011).
- Cibulka, R.; Siroka, R.; Trefil, L.; Racek, J. and Vesela, E.,** Measurement of Carnitine in haemodialysis patients, adaptation of an enzymatic photometric method for an automatic analyzer. *Clinical Chemistry and Laboratory Medicine*; 44(8): 983 -986(2006).
- Crook, M. A.,** *Clinical biochemistry and metabolic medicine*, 8<sup>th</sup> Edition. Hodder & Stoughton Ltd, London, pp: 36-58, pp: 310-324(2012).
- Cunningham, B.A.; Wang, J.L.; Berggard, I. and Peterson, P.A.,** Determination of  $\beta$ 2-Microglobulin using Double Antibody Sandwich Technique (ELISA) (1973).
- Dacie, J.V. and Lewis, S.M.,** *Practical hematology*, 7<sup>th</sup> Edition. Churchill Livingstone, Edinburgh, London, pp: 12-17(1995).

- Dean, J.A.**, "Flame photometry " 1<sup>st</sup> Edition. Mc-Graw-Hill Book Co., New York(1960).
- Debska-Slizien, A.; Owczarzak, A.; Kunicka, D.; Krol, E.; Lysiak-Szydłowska, W.; and Rutkowski, B.**, Erythrocyte metabolism and renal anemia in hemodialyzed patients supplemented with L-carnitine. *International Journal of Nephrology & Urology*; 3(1): 23-33(2011).
- Dennen, P.; Douglas, I.S. and Anderson, R.**, Acute kidney injury in the intensive care unit: An update and primer for the intensivist. *Critical Care Medicine*; 38(1):261-275(2010).
- Duranay, M.; Akay, H.; Yilmaz, F.M.; Senes, M.; Tekeli, N. and Yucel, D.**, Effects of L-carnitine infusions on inflammatory and nutritional markers in haemodialysis patients. *Journal of Nephrology, Dialysis and Transplantation*; 21(11): 3211–3214(2006).
- El-Khatib, M.T.**, The role of inflammation on iron and erythropoietin resistance. *Journal of Nephrology and Renal Transplantation*; 2(2): 45-54(2009).
- El-Maddawy, Z.Kh.**, Modulation of gentamicin-induced testicular and brain damage in rats. *Global Journal of Pharmacology*; 8 (3): 284-293(2014).
- Erdem, A.; Gundogan, N.U.; Usubutun, A.; Kilinc, K.; Erdem, S. R.; Kara, A. and Bozkurt, A.**, The protective effect of taurine against gentamicin-induced acute tubular necrosis in rats. *Journal of Nephrology, Dialysis and Transplantation*; 15(8):1175-1182(2000).
- Elsayed, M.; Elkomy, A.; Aboubakr, M. and Morad, M.**, Tissue residues, hematological and biochemical effects of tilmicosin in broiler chicken. *Veterinary Medicine International*; 2014:1-6(2014).
- Elyazji, N.R. And Abdel-Aziz, I.**, Some hematological and physiological changes associated and physiological changes associated with *gentamicin* and/or novalgin injection in rabbits. *International Journal of Pharmaceutical, Chemical and Biological Sciences*; 3(1): 172-181(2013).
- Erel, O.**, A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. *Clinical Biochemistry*; 37(4):277-285(2004).
- Erel, O.**, A new automated colorimetric method for measuring total oxidant status. *Clinical Biochemistry*; 38(12):1103-1111(2005).

- Gebaly, Z.M.; Ramadan, B.K., and Hamouda, M.H.**, The protective effect of L - carnitine on paracetamol-induced nephrotoxicity in adult male albino rats(Microscopic and Biochemical studies). *Journal of American Science*; 8(12):906-917(2012).
- Gonick, H.C.**, Nephrotoxicity of cadmium & lead. *Indian Journal of Medical Research*; 128(4): 335-352(2008).
- Gulcelik, N.E. and Kayataş, M.**, Importance of serum ferritin levels in patients with renal failure. *Nephron Journal*; 92(1):230-231(2002).
- Hales, M.; Solez, K. and Kjellstrand, C.**, The anemia of acute renal failure: association with oliguria and elevated blood urea. *Renal failure*;16(1):125-31(1996).
- Heibashy, M.I.A.; El-Nahala, A.M.; Ibrahim, A.I. and Saleh, S.Y.A.**, Comparative study between dimethyl sulfoxide (DMSO), allopurinol and urate oxidase administration in nephrotoxic rats induced with gentamicin. *Arab Journal of Nuclear Sciences and Applications*; 43(1):281-289(2010).
- Hennesy, D.J.; Reid, G.R.; Smith, F.E. and Thompson, S.L.**, Ferene : a new spectrophotometric reagent for iron. *Canadian Journal of Chemistry*; 62:721-724(1984).
- Horl, W.H.**, Adjunctive therapy in anaemia management. *Journal of Nephrology, Dialysis and Transplantation*; 17(5): 56-59(2002).
- Hozayen, W.; Bastawy, M. and Elshafeey, H.**, Effects of aqueous purslane (portulaca oleracea) extract and fish oil on gentamicin nephrotoxicity in albino rats. *Nature and Science*; 9(2):47-62(2011).
- Hur, E.; Garip, A.; Camyar, A.; Ilgun, S.; Ozisik, M.; Tuna, S.; Olukman, M.; Ozdemir, Z.N.; Sozmen, E.Y.; Sen, S.; Akcicek, F. and Duman, S.**, The Effects of Vitamin D on Gentamicin-Induced Acute Kidney Injury in Experimental Rat Model. *International Journal of Endocrinology*; 2013: 1-7(2013).
- Karadeniz, A.; Simsek, N. and Cakir, S.**, Haematological effects of dietary L-carnitine supplementation in broiler chickens. *Revue de Medecine Veterinaire*; 159 (8-9): 437 – 443(2008).
- Khan, M.R.; Badar, I. and Siddiquah, A.**, Prevention of hepatorenal toxicity with *Sonchus asper* in gentamicin treated rats. *BMC Complementary and Alternative Medicine* ; 2011: 11:113(2011).

- Kocha, T.; Yamaguchi, M.; Ohtaki, H.; Fukuda, T. and Aoyagi, T.,** Hydrogen peroxide-mediated degradation of protein: different oxidation modes of copper- and iron-dependent hydroxyl radicals on the degradation of albumin. *Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology*; 1337(2):319–326(1997).
- Kudoh, Y.; Aoyama, Sh.; Torii, T.; Chen, Q.; Nagahara, D.; Sakata, H. and Nozawa, A.,** Long-term effects of oral L-carnitine supplementation on anemia in chronic hemodialysis. *Cardiorenal Medicine*; 4(1):53–59(2014).
- Kusmic, C.; Picano, E.; Busceti, C.L.; Petersen, C. and Barsacchi, R.,** The antioxidant drug dipyrindamole spares the vitamin E and thiols in red blood cells after oxidative stress. *Cardiovascular Research*; 47(3):510-514(2000).
- Lin, Q. and Beiyi, L.,** Relationship between changes of plasma endothelin (ET) level, ATPase activity of erythrocyte membrane and development of nephropathy in patients with pregnancy induced hypertension. *Journal of Radioimmunology*; 21(3): 209-210(2008).
- Lobetti, R.G. and Joubert, K.E.,** Effect of administration of Nonsteroidal anti-inflammatory drugs before surgery on renal function in clinically normal dogs. *American Journal of Veterinary Research*; 61(12):1501-1507(2000).
- Lobo, V.; Patil, A.; Phatak, A. and Chandra, N.,** Free radicals, antioxidants and functional foods: Impact on human health. *Pharmacogn Rev.*; 4(8): 118–126(2010).
- Malaguarnera, M.; Vacante, M.; Giordano, M.; Motta, M.; Bertino, G.; Pennisi, M.; Neri, S.; Malaguarnera, M.; Volti, G.L. and Galvano, F.,** L-carnitine supplementation improves hematological pattern in patients affected by HCV treated with Peg interferon- $\alpha$  2b plus ribavirin. *World Journal of Gastroenterology*; 17(39): 4414-4420(2011).
- Mansour, H.H.,** Effect of L-carnitine on endothelial dysfunction markers in diabetic-irradiatedrats. *International journal of Toxicology and Applied Pharmacology*; 3(1): 1-9(2013).
- Martinez-Salgado, C.; Eleno, N.; Morales, A.I.; Perez-Barriocanal, F.; Arevalo, M. and Lopez-Novoa, J.M.,** Gentamicin treatment induces simultaneous mesangial proliferation and apoptosis in rats. *Kidney International*; 65(6): 2161–2171(2004).
- Matsumoto. Y.; Amano, I.; Hirose, S.; Tsuruta, Y.; Hara, S.; Murata, M. and Imai, T.,** Effects of L-carnitine supplementation on renal anemia in poor responders to erythropoietin. *Blood Purification*; 19(1):24-32(2001).

- Mohamed, N.E. and Farghaly, A.A.**, Evaluation of the protective effect of L-carnitine on radiation induced free oxygen radicals and genotoxicity in male mice. *Researcher*; 1(6):7-15(2009).
- Nand, N.; Yadav, R.K.; Aggarwal, H.K.; Yadav, A. and Sharma, M.**, To study the effects of L-carnitine administration on anaemia and oxidative stress in haemodialysed patients. *Journal Indian Academy of Clinical Medicine*, 9(4): 268-273(2008).
- Naeshiro, I.; Ishimura, Y.; Chatani, F. and Sato, S.**, Possible mechanism for the anaemia induced by gentamicin in rats. *Comparative Haematology International*; 7(4): 220-225(1997).
- Nagano, N.; Koumegawa, J.; Arai, H.; Wada, M. and Kusaka, M.**, Effect of recombinant human erythropoietin on new anaemic model rats induced by gentamicin. *J Pharm Pharmacol.*;42(11):758-62(1990).
- Nikolaos, S.; George, A.; Telemachos, T.; Maria, S.; Yannis, M. and Konstantinos, M.**, Effect of L-carnitine supplementation on red blood cells deformability in hemodialysis patients. *Renal Failure*; 22(1):73-80(2000).
- Parlakpınar, H.; Tasdemir, S.; Polat, A.; Bay-Karabulut, A.; Vardi, N.; Ucar, M. and Acet, A.**, Protective role of caffeic acid phenethyl ester (CAPE) on gentamicin-induced acute renal toxicity in rats. *Toxicology*; 207(2):169-177(2005).
- Pedraza-Chaverri, J.; Barrera, D.; Maldonado, P.D.; Chirino, Y.; Macías-Ruvalcaba, N.A.; Medina-Campos, O.N.; Castro, L.; Salcedo, M. and Hernandez-Pando, R.**, S-allylmercaptocysteine scavenges hydroxyl radical and singlet oxygen *in vitro* and attenuates gentamicin-induced oxidative and nitrosative stress and renal damage *in vivo*. *Bio Med Central Clinical Pharmacology*; 4(5):1-13(2004).
- Peres, L.A.B. and Junior, A.D.C.**, Acute nephrotoxicity of cisplatin: Molecular mechanisms. *Jornal Brasileiro de Nefrologia*; 35(4):332-340(2013).
- Pourabbas, A.; Fallah, F.; Mahdavi, R. and Aliasgarzadeh, A.**, Correlation of serum free carnitine with serum ferritin and vitamin C levels in type II diabetic in men. *Iranian Journal of Public Health*; 42(7): 767-774(2013).
- Ragab, S.M. and Mahfouz, R.G.**, L-carnitine ameliorates the iron mediated DNA degradation in peripheral leukocytes of  $\beta$ -thalassemic children. *Egyptian Journal of Medical Human Genetics*; 11(1):17-31(2010).

- Reisfeld, B.; Metzler, C. P.; Lyons, M. A.; Mayeno, A. N.; Brooks, E. J. and DeGroot, M. A.,** A Physiologically Based Pharmacokinetic Model for Capreomycin. *Antimicrobial Agents and Chemotherapy*; 56(2): 926–934(2012).
- Saleh, A.A.S.,** Synergistic effect of N-acetyl cysteine and folic acid against aspartame- induced nephrotoxicity in rats. *International Journal of Advanced Research*; 2(5):363-373(2014).
- Sener, G.; Paskaloglu, K.; Satiroglu, H.; Alican, I.; Kaçmaz, A. and Sakarcan, A.,** L-carnitine ameliorates oxidative damage due to chronic renal failure in rats. *Journal of Cardiovascular Pharmacology*; 43(5):698-705(2004).
- Servais, H.; Ortiz, A.; Devuyst, O. ; Denamur, S.; Tulkens, P. M. and Mingot-Leclercq, M.P.,** Renal cell apoptosis induced by nephrotoxic drugs: cellular and molecular mechanisms and potential approaches to modulation. *Apoptosis*; 13:11–32(2008).
- Shah, S.V.; Baliga, R.; Rajapurkar, M. and Fonseca. V.A.,** Oxidants in Chronic Kidney Disease. *American Society of Nephrology*; 18: 16–28(2007) .
- Shi, Ch. and Pamer, E.G.,** Monocyte recruitment during infection and inflammation. *Nature Reviews: Immunology*; 11: 762-772(2011).
- Silan, C.; Uzun, O.; Comunoğlu, N.U.; Gokçen, S. ;Bedirhan, S. and Cengiz, M.,** Gentamicin-induced nephrotoxicity in rats ameliorated and healing effects of resveratrol. *Biol Pharm Bull.*; 30(1):79-83(2007).
- Sirolli, V.; Rossi, C.; Di Castelnuovo, A.; Felaco, P.; Amoroso, L.; Zucchelli, M.; Ciavardelli, D.; Di Ilio, C.; Sacchetta, P.; Bernardini, S.; Arduini, A.; Bonomini, M. and Urbani A.,** Toward personalized hemodialysis by low molecular weight amino-containing compounds: Future perspective of patient metabolic fingerprint. *Blood Transfusion*; 10(2):78-88(2012).
- Soliman, K.M.; Abdul-Hamid, M. and Othman, A.I.,** Effect of carnosine on gentamicin-induced nephrotoxicity. *Med Sci Monit.*; 13(3):73-83(2007).
- Sukanya, L.; Prasong, T.; Nongkran, P.; Pachern, P.; Sappaporn, S. and George J. F.,** Sensitive sandwich enzyme immunoassay for serum ferritin on microtitre plates. *Annals of Clinical Biochemistry Journal*; 18:48-53(1981).
- Tietz, N.W.; Burtis, C.A.; Ashwood, E.R. and Saunders, W.B.,** clinical chemistry, 3<sup>rd</sup> Edition. Saunders, Philadelphia, pp:1699-1703(1999).

- Toptas, B.; Baykal, A.; Yesilipek, A.; Isbir, M.; Kupesizc, A.; Yalcind, O. and Baskurt, O.K.,** L-carnitine deficiency and red blood cell mechanical impairment in  $\beta$ -thalassemia major. *Clinical Hemorheology and Microcirculation*; 35(3):349-357(2006).
- Traina, G.,** Update on critical evidence for use of carnitine analogs in clinical practice in CNS disorders. *Nutrition and Dietary Supplements*; 3:77-87(2011).
- Uchendu, C.; Ambali, S.F.; Yakub, S.L.; Lasisi, O.I. and Umosen, A.J.,** Comparative effects of vitamin C and Acetyl-L-carnitine on subacute Chlorpyrifos-induced erythrocyte osmotic fragility in wistar rats. *Advances in Applied Science Research*; 2 (5):297-302(2011).
- Ustundag, S.; Sen, S.; Yalcin, O.; Ciftci, S.; Demirkan, B. and Ture, M.,** L-carnitine ameliorates glycerol-induced myoglobinuric acute renal failure in rats. *Renal Failure*; 31(2):124-133(2009).
- Uzum, A.; Toprak, O.; Gumustas, M.K.; Ciftci, S. and Sen S.,** Effect of vitamin E therapy on oxidative stress and erythrocyte osmotic fragility in patients on peritoneal dialysis and hemodialysis. *Journal of Nephrology*, 19(6):739 - 745(2006).
- Vanella, A.; Russo, A.; Acquaviva, R.; Campisi, A.; Di Giacomo, C.; Sorrenti, V. and Barcellona, M.L.,** L-propionyl-carnitine as superoxide scavenger, antioxidant, and DNA cleavage protector. *Cell Biology and Toxicology*; 16(2):99-104(2000).
- Wadhwa, N.; Mathew, B.B.; Jatawa, S.K. and Tiwari, A.,** Lipid peroxidation: Mechanism, models and significance. *INT J CURR SCI*.;3: 29-38(2012).
- Wang, L.; Xu, Z. R.; Jia, X. Y.; Jiang, J. F. and Han, X. Y.,** Effects of Arsenic ( $As^{III}$ ) on Lipid Peroxidation, Glutathione Content and Antioxidant Enzymes in Growing Pigs. *Asian-Aust. J. Anim. Sci.*; 19(5): 727-733(2006).
- Whiting, P. H. and Brown, P. A. J.,** The relationship between enzymuria and kidney enzyme activities in experimental gentamicin nephrotoxicity. *Renal Failure*; 18(6):899–909(1996).
- Yaman, I. and Balikci, E.,** Protective effects of nigella sativa against gentamicin-induced nephrotoxicity in rats. *Exp Toxicol Pathol.*; 62(2):183-190(2010).
- Ye, J.; Li, J.; Yu, Y.; Wei, Q.; Deng, W. and Yu, L.,** L-carnitine attenuates oxidative injury in HK-2 cell via ROS-mitochondrial pathway. *Regulatory Peptides*; 161(1-3):58-66(2010) .

## تأثير ل-كارنيتين على الجنتاميسين المسبب للفشل الكلوي والانيميا في ذكور الجرذان البيضاء البالغة

نفيسة حسين مكي<sup>1</sup>, محمد اسلام حبشي<sup>2</sup>, علا محمود محمود<sup>3</sup>, هبة ابوبكر يوسف احمد<sup>4</sup>

قسم علم الحيوان، كلية العلوم، جامعة عين شمس<sup>1</sup>

قسم التطبيقات البيولوجية مركز البحوث النووية- هيئة الطاقة الذرية<sup>2</sup>

قسم أمراض الدم، معهد بحوث تيودور بلهارس، القاهرة، مصر<sup>3</sup>

قسم علم الحيوان، كلية البنات، جامعة عين شمس<sup>4</sup>

أجريت هذه الدراسة لتقييم تأثير ل-كارنيتين على الفشل الكلوي والانيميا المحدث بالجنتاميسين في ذكور الجرذان البيضاء. قرنت مجموعة الجرذان العادية الضابطة (21 جرد، حقنت بالمحلول الملحي) ومجموعة الجرذان المصابة بالفشل الكلوي (49 جرد) وقد احدث الفشل الكلوي بالحقن بريتونيا بالجنتاميسين 80 مللي جرام/كيلوجرام من وزن الجسم لمدة 10 ايام و اخذ 7جرذان من كل مجموعة وذبحت لتقدير المعايير المدروسة. الجرذان المتبقية من المجموعة الضابطة اسخدمت كمجموعة ضابطة (المجموعة 1) (14 جرد)، وال 42 المتبقية والمصابة بالفشل الكلوي قسمت لمجموعات فرعية: المجموعة الضابطة الفرعية 2 وتشمل الجرذان المصابة بالفشل الكلوي (14 جرد)، المجموعة الفرعية 3 وتضم الجرذان المصابة بالفشل الكلوي والمعالجة بريتونيا ب ل-كارنيتين (300 مللي / كيلوجرام/ يوم) (14 جرد) لمدة 15 و 30 يوما. المجموعة الفرعية 4 وتضم الجرذان المصابة بالفشل الكلوي و المعالجة بريتونيا ب ل-كارنيتين (600 مللي / 14 جرد) لمدة 15 و 30 يوما. في نهاية كل فترة، تم ذبح 7جرذان من كل مجموعة. (كيلوجرام/ يوم) اوضحت النتائج من حقن الجنتاميسين ارتفاعا في مستوى ميكروجلوبولين ب 2، البولينا، الكرياتينين، اليوتاسوم، الاكسدة الكلية، الهشاشة الاسموزية، الفيرتين، الحديد و السعة الكلية لارتباط الحديد و انخفاض البروتينات الكلية، الصوديوم، اجمالى مضادات الاكسدة، كريات الدم الحمراء و تركيز الهيموجلوبين بالمقارنة مع مجموعة العادية الضابطة. بعد ذلك تمت معالجة الجرذان المصابة بالفشل الكلوي ب ل-كارنيتين وأظهرت الدراسة أن العلاج ب ل-كارنيتين احدث تصحيح ملحوظا في جميع المعايير السابقة البيوكيميائية والدموية وهذا هو الغرض من هذا العمل دراسة التحسن المحدث ب ل-كارنيتين على الفشل الكلوي و الانيميا من استخدام الجنتاميسين في معالجة الجرذان وتحديد علاجا للكلية وجرعة محددة لتكون مجالاً للبحث